# To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose Regimen of Ferroquine and Artefenomel in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria

> **NCT02497612** · PHASE2 · TERMINATED · sponsor: **Sanofi** · enrollment: 377 (actual)

## Conditions studied

- Plasmodium Falciparum Infection

## Interventions

- **DRUG:** Ferroquine SSR97193
- **DRUG:** Artefenomel
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02497612
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-07-25
- **Primary completion:** 2019-09-23
- **Final completion:** 2019-09-23
- **Target enrollment:** 377 (ACTUAL)
- **Why stopped:** All treatment arms met the futility criteria for efficacy during the pre-planned interim analysis, therefore the study was stopped.
- **Last updated:** 2022-03-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02497612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02497612, "To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose Regimen of Ferroquine and Artefenomel in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02497612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*